Journal of Clinical Endocrinology & Metabolism, Vol 65, 732-737, Copyright © 1987 by Endocrine Society

ARTICLES

Studies of acute effects of insulin-like growth factors I and II in human fat cells

J Bolinder, A Lindblad, P Engfeldt and P Arner
Department of Medicine, Huddinge Hospital, Karolinska Institute, Sweden.

The acute metabolic effects and receptor binding of insulin-like growth factors (IGFs) I and II were studied in human adipose tissue. The IGFs inhibited fat cell glycerol release and stimulated adipocyte 3-O- methylglucose transport and adipose tissue glucose oxidation as effectively as did insulin, but the biological potencies of the IGFs, on a molar basis, were 600-1000 times less than that of insulin. The insulin dose-response curve for antilipolysis gradually shifted to the left in the presence of submaximally and maximally effective IGF-I concentrations, whereas no additive response was found when fat cells were incubated with maximally effective concentrations of insulin and the IGFs. Adipocyte [125I]IGF-I and -II binding was low and was not inhibited by excess unlabeled IGF. In contrast, IGF-I inhibited [125I]insulin binding with a molar potency 1600 times lower than that of native insulin. In adipose tissue segments obtained from patients with untreated noninsulin-dependent diabetes mellitus, IGF-I and insulin inhibited glycerol release in a normal way. Conversely, neither insulin nor IGF-I increased the rate of glucose oxidation significantly above the nonhormone-stimulated level. We conclude that human fat cells lack specific cell surface IGF-binding sites. However, the IGFs definitely produce acute insulin-like effects in the human adipocyte, which seems to be mediated via the insulin receptor.

This article has been cited by other articles:

				T. Saukkonen, F. Shojaee-Moradie, R. M. Williams, R. Amin, K. C. Yuen, A. Watts, C. L. Acerini, A. M. Umpleby, and D. B. Dunger Effects of Recombinant Human IGF-I/IGF-Binding Protein-3 Complex on Glucose and Glycerol Metabolism in Type 1 Diabetes. Diabetes, August 1, 2006; 55(8): 2365 - 2370. [Abstract] [Full Text] [PDF]

				H. L. Simpson, N. C. Jackson, F. Shojaee-Moradie, R. H. Jones, D. L. Russell-Jones, P. H. Sonksen, D. B. Dunger, and A. M. Umpleby Insulin-Like Growth Factor I Has a Direct Effect on Glucose and Protein Metabolism, But No Effect on Lipid Metabolism in Type 1 Diabetes J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 425 - 432. [Abstract] [Full Text] [PDF]

				T. Pratipanawatr, W. Pratipanawatr, C. Rosen, R. Berria, M. Bajaj, K. Cusi, L. Mandarino, S. Kashyap, R. Belfort, and R. A. DeFronzo Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects Am J Physiol Endocrinol Metab, June 1, 2002; 282(6): E1360 - E1368. [Abstract] [Full Text] [PDF]

				A. L. Ogilvy-Stuart, M. A. Soos, S. J. Hands, M. Y. Anthony, D. B. Dunger, and S. O'Rahilly Hypoglycemia and Resistance to Ketoacidosis in a Subject without Functional Insulin Receptors J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3319 - 3326. [Abstract] [Full Text] [PDF]